Claudin-4 Expression Decreases Invasiveness and Metastatic Potential of Pancreatic Cancer

Patrick Michl, Claudia Barth, Malte Buchholz, Markus M. Lerch, Monika Rolke, Karl-Heinz Holzmann, Andre Menke, Heiko Fensterer, Klaudia Giehl, Matthias Lörhr, Gerhard Leder, Takeshi Iwamura, Guido Adler, and Thomas M. Gress

Department of Internal Medicine I, University Hospital [P. M., C. B., M. B., M. R., K.-H. H., A. M., H. F., G. A., T. M. G.], Department of Pharmacology [K. G.], and Department of Surgery I [G. L.], University of Ulm, 89061 Ulm, Germany; Department of Medicine B, Westfälische Wilhelms-Universität, D-48129 Münster, Germany [M. M. L.]; Department of Medicine IV, Medical Faculty Mannheim, University of Heidelberg at Mannheim, D-68167 Mannheim, Germany [M. L.]; and Department of Surgery I, Miyazaki Medical College, Miyazaki, 889-1601, Japan [T. I.]

ABSTRACT

Claudin-4 has been identified as an integral constituent of tight junctions and has been found to be highly expressed in pancreatic cancer. The aim of the present study was to elucidate the effect of claudin-4 on growth and metastatic potential in pancreatic cancer cells, as well as the regulation of claudin-4 by oncogenic pathways. Claudin-4 was stably overexpressed in SUIT-2 pancreatic cancer cells, and its effect on invasion and growth in vitro was examined by using two-chamber invasion assays, soft agar assays, and fluorescence-activated cell sorter analysis. Claudin-4 localization was characterized by light and electron microscopy, and pulmonary colonization was analyzed in vivo after injection of claudin-4 overexpressing cells into the tail vein of nude mice. Overexpression of claudin-4 was associated with significantly reduced invasive potential in vitro and inhibited colony formation in soft agar assays. In vivo, tail vein-injected claudin-4 overexpressing cells formed significantly less pulmonary metastases in comparison with mock-transfected cells. These effects were not caused by changes in proliferation, cell cycle progression, or matrix metalloproteinase gelatinolytic activity, but were paralleled by increased cell contact formation. Moreover, proinvasive transforming growth factor β was able to down-regulate claudin-4 in PANC-1 cells. Inhibition of Ras signaling by using dominant-negative Ras and specific inhibitors of both downstream effectors mitogen-activated protein kinase/ERK and phosphatidylinositol 3-kinase also decreased claudin-4 expression. Our findings identify claudin-4 as a potent inhibitor of the invasiveness and metastatic phenotype of pancreatic cancer cells, and as a target of the transforming growth factor β and Ras/Raf/extracellular signal-regulated kinase pathways.

INTRODUCTION

Tight junctions are the most apical component of intercellular junctional complexes, thereby establishing cell polarity and functioning as major determinants of paracellular permeability (1). The family of claudins, which form integral constituents of tight junctions (2), consists of at least 20 transmembrane proteins and represents a major factor in establishing the intercellular barrier (3). Many members of the claudin family show a distinct organ-specific distribution pattern within the human body (4).

Claudin-4 consists of 209 amino acids and contains four putative transmembrane segments (5). In previous studies, we identified claudin-4 as overexpressed in pancreatic cancer in various expression profiling approaches using representational difference analysis and DNA array technology (6, 7). To date, the physiological relevance of this finding remains unknown.

Interestingly, claudin-4 and, with a lesser affinity, claudin-3 have been described to function as receptors for CPE (5). CPE is known to injure intestinal epithelial cells by an increase in membrane permeability resulting in loss of the osmotic equilibrium and subsequent cell death (8). In pancreatic cancer cells, we observed a cytotoxic effect of CPE in vitro and in vivo, which was restricted to claudin-4 expressing cells. These findings might open a novel treatment approach for claudin-4 expressing solid tumors using CPE (9). Our observations were confirmed recently by Long et al. (10), who described a cytotoxic effect of CPE in prostate cancer cells overexpressing claudin-3 and claudin-4.0. Claudin-4 was also found recently to be overexpressed in ovarian cancer (11) underlining the therapeutic potential of the CPE-claudin-4 interaction in a variety of solid tumors.

Several claudins have been shown to be regulated by oncogenes and tumor promoting growth factors. Transfection of oncogenic Raf-1 into a salivary gland epithelial cell line resulted in down-regulation of claudin-1 and loss of tight junction function (12). In Ras-transformed MDCK cells, claudin-1 was absent from cell-cell contacts but was reasssembled to the cell membrane after blocking the mitogen-activated protein kinase pathway, paralleled by tight junction formation (13). TGF-β, a potent modulator of invasion and metastasis in pancreatic cancer (14, 15), has been demonstrated to perturb the tight junction permeability and assembly of claudin-11 in Sertoli cells (16). Furthermore, claudins have been shown to modify tumor invasion by the regulation of MMPs. Several members of the claudin-family such as claudin-2 and claudin-5 are able to activate membrane-type 1-MMP-mediated pro-MMP-2 processing (17). These reports indicate that members of the claudin-family are modulated during the process of oncogenic transformation and may play an important role in influencing tumor progression and invasion.

On the basis of our previous observations, the aim of the present study was to characterize the biological role of claudin-4 up-regulation in several solid tumors including pancreatic carcinoma (9). Therefore, we investigated the effect of claudin-4 on proliferation, invasion, and metastatic behavior of pancreatic cancer cells, and examined the regulatory effects of both TGF-β and oncogenic Ras including its major downstream effectors on claudin-4 expression.

MATERIALS AND METHODS

Materials and Cell Lines. Human tissue from patients with ductal adenocarcinoma of the pancreas were provided by the Department of Surgery at the University of Ulm and by the Hungarian Academy of Sciences (Budapest, Hungary). All of the tissues were obtained after approval by the local ethics committees.

Received 3/1/03; revised 5/28/03; accepted 7/21/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by grants of the Deutsche Forschungsgemeinschaft (SFB 518/Project B1) and the European Community (QLG1-CT-2002-01196; to T. M. G.) and by the Sander-Stiftung (project 2001.053.1; to P. M. and T. M. G.), and Deutsche Krebshilfe (10-2031-Le; to M. M. L.).

2 To whom requests for reprints should be addressed, at Universitäät Ulm, Abteilung Innere Medizin I, Robert-Koch-Str. 8, 89081 Ulm, Germany. Phone: 49-731-50024385; Fax: 49-731-50024302; E-mail: thomas.gress@medizin.uni-ulm.de.

3 The abbreviations used are: CPE, Clostridium perfringens enterotoxin; TGF, transforming growth factor; MMP, matrix metalloproteinase; MEK, mitogen-activated protein/ extracellular signal-regulated kinase kinase; PI3K, phosphatidylinositol 3-kinase; FACS, fluorescence-activated cell sorter; EM, electron microscopy.
The human pancreatic cancer cell lines were obtained from the indicated suppliers: PANC-1 (European Collection of Animal Cell Cultures, Salisbury, United Kingdom), SUIT-2 clones S2-007 and S2-028 (Takeshi Iwamura, Miyazaki Medical College, Miyazaki, Japan; Ref. 18). PANC-1 cells were stably transfected with human dominant-negative H-Ras (S17N) cloned into the pEGFP-C expression vector (Clontech, Palo Alto, CA). PANC-1 cells stably overexpressing TGF-β1 were generated as described previously (19). All of the cell lines were incubated in DMEM (Life Technologies, Inc., Baltimore, MD) and 10% FCS (Life Technologies, Inc.).

The rabbit polyclonal antibody against claudin-4 was obtained from S. Tsukita and was used as described previously (20). TGF-β was purchased from R&D Systems (Minneapolis, MN). The inhibitors U0126 and LY294002 were purchased from Sigma (St. Louis, MO).

Overexpression of Claudin-4 in S2-007 Cells. A full-length claudin-4 cDNA was PCR-amplified from normal pancreas tissue using the 5′-primer CCGTACAAGGCACCTGAACTTGG and 3′-primer GCCAGCTTGGACCCGGCGCACCTTTTA. A 673-bp PCR product containing nucleotides 183–812 of human claudin-4 (Accession No. NM_001305) was sequence-verified and cloned into pRc/CMV (Invitrogen, Karlsruhe, Germany) and 10% FCS (Life Technologies, Inc.) and 10% FCS (Life Technologies, Inc.).

For immunodetection, blots were incubated with a rabbit polyclonal antibody against mouse claudin-4 (1:1000; Ref. 20) followed by peroxidase-coupled secondary antibody, a Cy3-labeled antirabbit IgG (dilution of 1:1000) (Jackson Immunoresearch Laboratories, West Grove, PA).

Semithin sections were studied by light microscopy and thin sections evaluated on a Philips EM10 electron microscope. In brief, SUIT-2 cells were fixed with 32% ethanol for 30 min and washed once with PBS. After resuspending in 500 μl PBS, 5 ml 80% ethanol (−20°C) were added dropwise while vortexing, and cells were incubated on ice for 30 min. Cells were centrifuged at 1500 rpm for 5 min and resuspended in 320 μl PBS. After RNase treatment cells were stained with propidium iodide according to standard methods. To minimize aggregates, the suspension was passed several times through a syringe and subsequently filtered through a 53 μm nylon mesh before analyzing in a FACScan flow cytometer (Becton Dickinson). Remaining aggregates were gated out before analysis. Doubles were excluded using the double discrimination method of the CellFit software (Becton Dickinson). The percentage of apoptotic nuclei was determined as described by the method of Nicoletti et al. (25). Cell cycle analysis was done using the WinMDI software, as well as the Modfit software (Becton Dickinson).

Invasion Assay. The invasive potential of the parental S2-007 and S2-028 cell lines, two claudin-4 overexpressing S2-007 clones and one vector-transfected S2-007 clone, was determined using a modified two-chamber invasion assay as described previously (14). Briefly, 12-well Transwell-plates (Costar, Cambridge, MA) with 8-μm pore size were coated with 1.2 diluted Matrigel (Becton Dickinson, Heidelberg, Germany). The lower chamber contained DMEM-medium with 10% FCS, and the upper chamber was filled with 1.5 × 10^5 tumor cells in DMEM with 1% FCS. Incubation times were 6, 12, and 28 h. After the incubation period, cells on the upper side of the membrane were wiped off, and the membrane was fixed in 4% paraformaldehyde and 0.25% glutaraldehyde. Cells on the lower side of the membrane were stained with 0.5% methylblue in 50% methanol and counted. All of the invasion assays were done in triplicate.

Soft Agar Assay. Soft agar assays were performed as described previously (23). Two × 10^5 cells of each S2-007 and S2-028 parental cell lines, as well as two claudin-4 overexpressing S2-007 clones and one mock-transfected S2-007 clone were seeded in DMEM/0.33% bacto-agar onto a bottom layer of DMEM/0.5% bacto-agar. Anchorage-independent growth was measured 2 weeks later by counting the colony number.

Zymography. The gelatinolytic activity of MMPs was determined in the supernatants of S2-007 cells with tetracyclin-inducible claudin-4 expression as described previously (15). For this purpose, cells were cultured in serum-free or 5% FCS-containing DMEM in the presence or absence of 2 μg/ml doxycyclin. After 24 h, supernatants were concentrated and the protein content was determined using the BCA Protein Assay Reagent (Pierce, Rockford, IL). Equal amounts of protein (20 μg/lane) were mixed with SDS sample buffer without reducing agents and incubated for 20 min at 37°C. Subsequently, samples were separated on a 7.5% PAGE containing 1 mg/ml gelatin for the detection of MMP activity (Invitrogen, Karlsruhe, Germany). After electrophoresis, gels were soaked for 1 h in 2.5% Triton X-100 to remove SDS and incubated for 16 h at 37°C in 50 mm Tris-HCl (pH 7.6) containing 150 mM NaCl, 5 mM CaCl_2, and 0.02% NaN_3. Gels were stained for 1 h in 4% methanol/10% acetic acid containing 0.5% Coomassie brilliant blue G250 and destained. Proteolytic activity was detected as clear bands on a blue background of the Coomassie blue-stained gel. Zymographic analyses were performed in at least three independent experiments.

Mouse Experiments. NMRI-nu/nu mice were propagated and maintained in a pathogen-free environment according to the guidelines of the local animal welfare committee. One × 10^6 cells of claudin-4 overexpressing S2-007 cells or mock-transfected cells dissolved in PBS (2 clones each; 6 mice/group) were injected into the tail vein of 5-week-old female NMRI nu/nu mice each. Five weeks after injection, the animals were sacrificed. Lungs, liver, and spleen were paraffin-embedded and examined histologically. Colonizations of the lungs were counted in 10 serial sections of each lung.

EM. EM analysis was performed as described previously (26). In brief, SUIT-2 cells were fixed in an iced solution of buffered 5% paraformaldehyde, embedded in Epon, postfixed, and contrasted with osmium, uranyl, and lead. Semithin sections were studied by light microscopy and thin sections evaluated on a Philips EM10 electron microscope.

RESULTS

Expression of Claudin-4 in SUIT-2 Pancreatic Cancer Cells and Pancreatic Carcinomas. Claudin-4 expression was studied in the SUIT-2 pancreatic cancer cell lines, which represent subclones from the same primary pancreatic tumor, but display different spontaneous metastatic potential in nude mice (18). Interestingly, subclone S2-028, which is known to have low metastatic and invasive potential (18), exhibited strong claudin-4 expression, whereas claudin-4 expression was very weak in the highly invasive subclone S2-007 (Fig. 1A). On the basis of this observation we hypothesized that expression of claudin-4 might be inversely correlated and modulate invasion. To elucidate the effect of claudin-4 on invasion, we stably transfected claudin-4 in the highly metastatic subclone S2-007 with weak endogenous claudin-4, and selected clones with a strong claudin-4 expression on the RNA and protein level (Fig. 1A) for additional analysis.

Immunocytochemistry of cell monolayer cultures grown on chamber slides showed a strong claudin-4 signal located at cell-cell contact sites in claudin-4 overexpressing cells consistent with tight junctions.
In contrast, parental or mock-transfected cells showed no claudin-4 labeling at these intercellular adhesion sites (Fig. 1B). When S2-007 cells were studied by EM, parent or mock-transfected cells were loosely connected by interspersed and sparsely present cell contacts that, at higher magnification, could be identified as adherens junctions and desmosomes (Fig. 1C, panels I and II), whereas tight junctions were rarely found. Claudin-4 expressing S2-007 cells, on the other hand, were tightly connected by a network of tight junctions that often occupied most of the cellular adhesion sites (Fig. 1C, panels III and IV).

To confirm these findings that were obtained by overexpressing claudin-4, we examined a series of six pancreatic adenocarcinomas immunohistochemically. As depicted in two representative tissues shown in Fig. 1D, claudin-4 immunostaining in each tissue was restricted to tumor cells, whereas no claudin-4 staining was found in the surrounding extracellular matrix compartment. Moreover, in tumors exhibiting ductal-like structures, claudin-4 was predominantly localized in the apical cell layers adjacent to the ductal lumen (Fig. 1D). Interestingly, claudin-4 expression tended to be stronger in well-differentiated tumors as compared with poorly differentiated tumors, a finding that has to be confirmed in a study using a larger series of tumor samples.
and are representative of three independent experiments; bars, ± SE. * indicates \( P < 0.05 \) as compared with parental S2-007 cells using unpaired double-sided \( t \) test with Bonferroni correction for multiple sampling.

**Figure 2.** A: Two-chamber invasion assay of parental, mock-transfected, and claudin-4 overexpressing S2-007 cells, as well as parental S2-028 cells. All assays were done in triplicate with at least two different claudin-4 overexpressing clones. B: quantitative evaluation of soft agar assays performed with parental S2-007 cells, mock-transfected S2-007 cells, claudin-4 overexpressing S2-007 cells, and parental S2-028 cells. All assays were done in triplicate. C, representative colonies formed by mock-transfected S2-007 cells, claudin-4 overexpressing S2-007 cells, and parental S2-028 cells, documented 10 days after seeding. Original magnification, 4-fold. Statistical data are expressed as mean and are representative of three independent experiments; bars, ± SE. * indicates \( P < 0.05 \) as compared with parental S2-007 cells using unpaired double-sided \( t \) test with Bonferroni correction for multiple sampling, where indicated.

**Effect of Claudin-4 Expression on Cell Invasion and Anchorage-independent Growth in Vitro.** To investigate the effect of claudin-4 on the invasive potential of S2-007 cells, we performed two-chamber assays. In all three of the examined claudin-4 overexpressing S2-007 clones, invasion was significantly reduced as compared with both parental S2-007 cells and mock-transfected S2-007 cells. The invasive potential of the claudin-4 overexpressing S2-007 cells, as assessed by the two-chamber assays, was closer to the invasive potential of the low-invasive S2-028 cells with high endogenous claudin-4 levels than to the parental S2-007 cells (Fig. 2A).

To examine whether claudin-4 overexpression also alters the ability for anchorage-independent growth as a measure for tumorigenic potential, soft agar assays were performed. Interestingly, claudin-4 transfected cells showed a significantly reduced colony formation, both in number and in size, as compared with parental or mock-transfected cells (Fig. 2B). Again, claudin-4 overexpressing S2-007 cells more closely resembled the low-invasive S2-028 cells with high endogenous claudin-4 levels than the parental S2-007 cells (Fig. 2C).

**Effect of Claudin-4 Expression on Lung Colonization in Vivo.** To examine whether the anti-invasive effect of claudin-4 in vitro has a physiological relevance in vivo, we injected two S2-007 clones stably overexpressing claudin-4 into the tail vein of \( /v/v \) mice and compared the occurrence of pulmonary colonization in claudin-4 overexpressing versus mock-transfected S2-007 clones after a period of 5 weeks. Interestingly, claudin-4 overexpression significantly reduced the number of pulmonary colonizations by \(~50\%\), as compared with mock-transfected cells (Fig. 3A). Furthermore, 5 of 16 mice injected with claudin-4 overexpressing cells did not show any evidence of lung metastases, as determined by 10 serial sections of each lung. In contrast, none of the control mice was free of lung metastasis upon sacrifice (Fig. 3B). Thus, the anti-invasive effect of claudin-4 could be confirmed in vivo.

**Effect of Claudin-4 Expression on Proliferation, Cell Cycle Progression, and MMP Activity.** To examine the possibility that overexpressed claudin-4 alters proliferation or cell cycle progression, we performed proliferation assays and FACS analysis with stably transfected claudin-4 overexpressing clones and mock-transfected clones. \([3\text{H}]\)Thymidine incorporation assays revealed no significant alterations of the proliferation rate of claudin-4 overexpressing clones (data not shown). In addition, FACS analysis showed neither altered cell cycle progression nor a significant fraction of apoptotic cells, neither in subconfluent or confluent cell populations (Fig. 4A).

Because a direct activating effect of several claudins including claudin-2 and -5 on pro-MMP-2 has been postulated recently (17), we wanted to rule out a modulatory effect of claudin-4 overexpression on activity of MMPs. Therefore, we performed gelatin zymographies as a screening test for the activity of gelatinolytic MMPs. However, claudin-4 overexpressing clones showed no altered pattern of MMP activity, particularly no alteration in MMP-2 at \( M_r \) 63,000 (Fig. 4B). Therefore, a direct or indirect modulation of MMP activity by claudin-4 appears unlikely.

**Modulation of Claudin-4 by TGF-β and Oncogenic Ras.** Tight junction structure and integrity are modulated by a variety of cyto-
kines and growth factors. Both the TGF-β and the Ras cascade have been shown to be of paramount importance for the development of the metastatic phenotype of tumor cells and tumor progression. In pancreatic carcinoma, TGF-β has been demonstrated as an important modulator of tumor progression (15). Despite of its direct growth-inhibitory effects in vitro, TGF-β is also known to strongly promote invasion of pancreatic cancer cells. To study the TGF-β responsiveness of claudin-4 we used exogenously added TGF-β as well as PANC-1 cells stably overexpressing TGF-β. Interestingly, in both systems claudin-4 expression was down-regulated by TGF-β (Fig. 5A). After addition of exogenous TGF-β, claudin-4 RNA decreased after 4 h, which was followed by a decrease in claudin-4 protein levels after 12 h (Fig. 5C).

More than 90% of pancreatic carcinomas have activating K-ras mutations (27). Therefore, we examined whether inhibition of downstream effectors of the Ras signaling pathway had an effect on claudin-4 expression. Furthermore, we used PANC-1 cells stably overexpressing dominant-negative H-Ras (S17N). In both systems, inhibition of Ras signaling was associated with decreased claudin-4 expression. Interestingly, both MEK and PI3K inhibition using the inhibitors UO126 and LY294002 led to a decrease in claudin-4 transcription within 4 h suggesting that several signaling effectors downstream of Ras are positively regulating claudin-4 (Fig. 5B). These effects were also observed on claudin-4 protein levels 12 h after addition of both inhibitors (Fig. 5C), after addition of UO126 the effect was present up to 24 h.

DISCUSSION

We have reported previously that claudin-4, one of the integral constituents of tight junctions, is overexpressed in the majority of pancreatic carcinomas and functions as a receptor for cytotoxic CPE, which is able to exert a cytotoxic effect specifically on claudin-4 positive tumor cells. Therefore, claudin-4 overexpressing tumors might represent a potential target for CPE-based therapeutic approaches (9). Thus far, increased claudin-4 levels have also been shown in prostate cancer (10), ovarian carcinoma (11), and in several other tumor cell lines (28), mainly by using high-throughput expression profiling approaches. On the basis of these observations, claudin-4 overexpression appears to be typical for adenocarcinomas with ductal, cystic, or glandular structures such as pancreatic, ovarian, and prostate cancer. However, the functional relevance of these findings is largely unknown.

In this study, we focused on the biological role of up-regulated claudin-4 in pancreatic cancer cells. We first demonstrated that overexpressed claudin-4 is mainly concentrated at cell-cell contacts. An increase in these cell-cell adhesion sites is ultrastructurally paralleled by an increased number of tight junctions in claudin-4 overexpressing...
cells. These findings are in accordance to observations by Van Itallie et al. (29) in claudin-4 overexpressing MDCK cells, who described an increase in the total content of TJ strands with a more elaborate and complex pattern of strands.

Interestingly, our functional in vitro data indicate that overexpression of claudin-4 is associated with decreased invasiveness, as demonstrated by two-chamber invasion assays. In addition, claudin-4 overexpression was also associated with a markedly diminished ability of S2-007 cells to anchor-independent growth in soft agar. We could confirm these observations in vivo and showed a significantly decreased lung colonization rate after tail vein injection of claudin-4 overexpressing cells in nude mice. By examining proliferation and cell cycle progression, we could rule out that the described effects are secondary to altered proliferation, cell cycle progression, or significantly increased apoptosis.

A role of tight junctions as a prerequisite for tumor cell invasion has been described in endothelial cells. The reduction of tight junctions in these cells was found to decrease paracellular resistance and to facilitate invasion of epithelial tumor cells through endothelial cell layers (30, 31). In epithelial tumor cells, the formation of junctional complexes including tight and adherent junctions has been shown to reduce the invasive potential (32). However, to our knowledge, the direct effect of claudins on invasion of tumor cells has not been examined systematically. Our data show for the first time that overexpressed claudin-4 confers a less invasive phenotype in vitro and in vivo. We were able to show that this is not likely to be caused by alterations in the activity of gelatinolytic MMPs, as it has been described previously for other members of the claudin family (17). In our ultrastructural studies we found an increase in tight junctions between neighboring claudin-4 overexpressing tumor cells. This leads to the conclusion that an increase in the density of cell-cell adhesions formed by tight junctions may represent a crucial impediment against the dissociation of pancreatic cancer cells from their original tumor. This, in turn, would prevent the invasion into neighboring tissues or the formation of distant metastases. A similar mechanism has been proposed for the E-cadherin-mediated development of epithelial polarity and the suppression of invasiveness of cancer cells, which is associated with increased cell contact formation (32).

Considering that claudin-4 is highly expressed in many pancreatic carcinomas (9) and several other solid tumors (10, 11), our in vitro and in vivo findings demonstrating claudin-4 as an anti-invasive factor appear somewhat surprising. On the basis of the immunohistochemical findings in our series of pancreatic carcinoma tissues, in which claudin-4 expression was higher in well-differentiated carcinomas (9) and several other solid tumors (10, 11), our in vitro and in vivo results showed a significantly decreased claudin-4 levels markedly. Despite its anti-invasive properties, the biological relevance of claudin-4 expression is somewhat surprising.

In summary, we showed that claudin-4 is overexpressed in pancreatic cancer and associated with decreased invasiveness in vitro and in vivo. This effect was morphologically associated with increased formation of tight junctions between tumor cells. Claudin-4 is negatively regulated by TGF-β and down-regulated by inhibition of the Ras signaling pathway. Our data clearly identify claudin-4 expression as an event that impairs the invasiveness and the metastatic potential of pancreatic cancer cells. Additional studies are warranted to investigate the role of claudin-4 expression, tumor invasion, and clinical outcome in pancreatic cancer patients. This might also characterize the types of patients, which might benefit from a possible CPE-based anticancer therapy targeting claudin-4.

REFERENCES


Claudin-4 Expression Decreases Invasiveness and Metastatic Potential of Pancreatic Cancer

Patrick Michl, Claudia Barth, Malte Buchholz, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/63/19/6265

Cited articles
This article cites 36 articles, 17 of which you can access for free at:
http://cancerres.aacrjournals.org/content/63/19/6265.full.html#ref-list-1

Citing articles
This article has been cited by 38 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/63/19/6265.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.